טוען...
Arsenic trioxide as a radiation sensitizer for (131)I-metaiodobenzylguanidine therapy: Results of a phase II study
Arsenic trioxide has in vitro and in vivo radiosensitizing properties. We hypothesized that Arsenic trioxide would enhance the efficacy of the targeted radiotherapeutic agent (131)I-metaiodobenzylguanidine ((131)I-MIBG), and tested the combination in a phase II clinical trial. METHODS: Patients with...
שמור ב:
| הוצא לאור ב: | J Nucl Med |
|---|---|
| Main Authors: | , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4976822/ https://ncbi.nlm.nih.gov/pubmed/26742708 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.115.161752 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|